Compare
Glucotrack, Inc. vs Autonomix Medical, Inc. vs RenovoRx, Inc. vs Bluejay Diagnostics, Inc.
| Latest fiscal year | Glucotrack, Inc. GCTKRevenue covers only part of its income (partial revenue) | Autonomix Medical, Inc. AMIX | RenovoRx, Inc. RNXT | Bluejay Diagnostics, Inc. BJDX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | $1.12M | n/a |
| Revenue growth (YoY) | n/a | n/a | n/m | n/a |
| Gross margin | n/a | n/a | 70.9% | n/a |
| Operating margin | n/a | n/a | n/m | n/a |
| Net margin | n/a | n/a | -994.5% | n/a |
| Net income | -$19.39M | -$16.71M | -$11.17M | -$6.85M |
| EPS (Diluted) | $31.22 | n/a | -$0.32 | -$15.25 |
| Operating cash flow | -$15.24M | -$12.28M | -$10.97M | -$6.05M |
| Free cash flow | -$15.34M | -$12.29M | -$10.97M | -$6.23M |
| Cash & equivalents | $7.38M | $7.00M | $7.02M | $5.16M |
| Total assets | $7.84M | $7.60M | $8.10M | $7.12M |
| Total liabilities | $5.01M | $1.71M | $2.67M | $1.14M |
| Shareholders' equity | $2.83M | $5.89M | $5.42M | $5.98M |
| Return on year-end equity | -685.6% | -283.5% | -206.0% | -114.6% |
| Shares outstanding | 910.7K | 11.41M | 36.61M | 604.5K |
Revenue, most recent five fiscal years
| Fiscal year | Glucotrack, Inc. | Autonomix Medical, Inc. | RenovoRx, Inc. | Bluejay Diagnostics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2026-03-31 | $1.12M Ended 2025-12-31 | $249.0K Ended 2022-12-31 |
| 1 year earlier | n/a | $0 Ended 2025-03-31 | $43.0K Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $0 Ended 2024-03-31 | n/a | n/a |
| 3 years earlier | n/a | $0 Ended 2023-03-31 | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |